FGFR2 fusion: Gene Variant Detail - Cancer Knowledgebase (CKB)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 44 of 44 entries

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT02465060	Phase II	Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT02546661	Phase I	Danvatirsen + Durvalumab Durvalumab + Selumetinib Fexagratinib Durvalumab + Olaparib Durvalumab Durvalumab + Fexagratinib Durvalumab + Vistusertib Adavosertib + Durvalumab	Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer (BISCAY)	Active, not recruiting	USA \| GBR \| FRA \| ESP \| CAN	0
NCT03390504	Phase III	Pembrolizumab Erdafitinib Docetaxel + Vinflunine	A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	8
NCT04083976	Phase II	Erdafitinib	A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)	Active, not recruiting	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| BRA \| BEL \| AUS \| ARG	4
NCT04233567	Phase II	Infigratinib	Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations	Active, not recruiting	USA	0
NCT04526106	Phase I	Lirafugratinib	REFOCUS: a First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with ICC and Other Advanced Solid Tumors	Active, not recruiting	USA \| SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| AUS	4
NCT04601857	Phase II	Futibatinib + Pembrolizumab	Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma	Active, not recruiting	USA \| FRA \| ESP	0
NCT05174650	Phase II	Atezolizumab + Derazantinib	Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements	Active, not recruiting	DEU	0
NCT02052778	Phase Ib/II	Futibatinib	A Study of TAS-120 in Patients With Advanced Solid Tumors	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	4
NCT02265341	Phase II	Ponatinib	Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions	Completed	USA	0
NCT02272998	Phase II	Ponatinib	Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.	Completed	USA	0
NCT02872714	Phase II	Pemigatinib	A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)	Completed	USA \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| BEL	1
NCT03230318	Phase II	Derazantinib	Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01)	Completed	USA \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CHE \| CAN \| BEL	1
NCT04045613	Phase Ib/II	Derazantinib Atezolizumab + Derazantinib	Derazantinib and Atezolizumab in Patients With Urothelial Cancer (FIDES-02)	Completed	USA \| POL \| ITA \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| AUT \| AUS	1
NCT04172675	Phase II	Erdafitinib Gemcitabine Mitomycin C	A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)	Completed	USA \| POL \| ITA \| GBR \| FRA \| ESP \| DEU \| CZE \| BRA \| BEL \| AUS \| ARG	5
NCT05253807	Phase II	Pemigatinib	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)	Completed	USA \| ITA \| FRA \| ESP \| DEU	0
NCT05267106	Phase II	Pemigatinib	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU	1
NCT06728410	Phase II	Durvalumab + Pemigatinib	A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement	Not yet recruiting	USA	0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Futibatinib Ipilimumab + Nivolumab Palbociclib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT02925234	Phase II	Crizotinib Sunitinib Niraparib Olaparib Lorlatinib Erdafitinib Talazoparib Dacomitinib Axitinib Panitumumab	The Drug Rediscovery Protocol (DRUP Trial) (DRUP)	Recruiting	NLD	0
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT05244551	Phase I	ABSK061	A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors	Recruiting	USA	1
NCT05316155	Phase I	Erdafitinib	Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer	Recruiting	USA \| NLD \| ESP \| DEU	1
NCT05627063	Phase I	ABSK121	A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors	Recruiting	USA	1
NCT05727176	Phase II	Futibatinib	Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4)	Recruiting	USA \| POL \| ITA \| ESP \| BRA \| AUS \| ARG	5
NCT05948475	Phase III	Tinengotinib	Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308)	Recruiting	USA \| POL \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| BEL \| AUT	3
NCT06160752	Phase I	TYRA-200	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)	Recruiting	USA	0
NCT06302621	Phase I	Afatinib + Pemigatinib	Pemigatinib + Afatinib in Advanced Refractory Solid Tumors	Recruiting	USA	0
NCT06319820	Phase III	Mitomycin C Gemcitabine Erdafitinib	A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| IRL \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| BRA \| BEL \| AUT \| ARG	4
NCT06653777	Phase II	Pemigatinib	Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells (AcSe PEMI)	Recruiting	FRA	0
NCT06906562	Phase II	Pemigatinib	A Phase II Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR Genetic Alterations	Recruiting	USA	0
NCT06439485	Phase II	Atezolizumab + Bevacizumab + Pemigatinib	Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion	Suspended	USA	0
NCT01948297	Phase I	Zoligratinib	Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations	Terminated	USA \| ESP	3
NCT02160041	Phase II	Infigratinib	BGJ398 for Patients With Tumors With FGFR Genetic Alterations	Terminated	USA	0
NCT02393248	Phase Ib/II	Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab	Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)	Terminated	USA \| DNK	0
NCT02608125	Phase I	PRN1371	A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma	Terminated	USA \| ESP	0
NCT03773302	Phase III	Cisplatin + Gemcitabine Infigratinib	Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations	Terminated	USA \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS	6
NCT03822117	Phase II	Pemigatinib	Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)	Terminated	USA \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE	2
NCT03834220	Phase II	Zoligratinib	Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)	Terminated	USA \| ROU \| POL \| NOR \| NLD \| HRV \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| CZE \| BRA \| BGR \| AUT \| AUS	6
NCT04088188	Phase I	Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib	Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma	Terminated	USA	0
NCT05565794	Phase II	Pemigatinib	Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements	Terminated	DEU	0
NCT04972253	Phase I	Infigratinib	Phase I BLASST-3 Trial ((BLASST)-3)	Withdrawn		0
NCT05216120	Phase II	Pemigatinib	Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas	Withdrawn	USA	0
NCT05510427	Phase I	Atezolizumab + Bevacizumab + Infigratinib	Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification	Withdrawn		0

Showing 1 to 44 of 44 entries

Filter rows:

Gene	FGFR2
Variant	fusion
Impact List	fusion
Protein Effect	unknown
Gene Variant Descriptions	FGFR2 fusion indicates a fusion of the FGFR2 gene, but the fusion partner is unknown.
Associated Drug Resistance
Category Variants Paths	FGFR2 mutant FGFR2 rearrange FGFR2 fusion

FGFR2 fusion - Gene Variant Detail

Contact

Filtering

Sorting

Filtering

Sorting